METTL3 and breast carcinoma: METTL3 predicts shorter overall survival in glioblastoma, longer survival in breast cancer [28], and is also highly expressed in OV and promotes cell proliferation, lesion formation, movement, invasion, and tumor formation, and indicates poor prognosis [29].